Asset Details
Do you wish to reserve the book?
Impact of perioperative use of GnRH agonist or dienogest on ovarian reserve after cystectomy for endometriomas: a randomized controlled trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Impact of perioperative use of GnRH agonist or dienogest on ovarian reserve after cystectomy for endometriomas: a randomized controlled trial
Do you wish to request the book?
Impact of perioperative use of GnRH agonist or dienogest on ovarian reserve after cystectomy for endometriomas: a randomized controlled trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Impact of perioperative use of GnRH agonist or dienogest on ovarian reserve after cystectomy for endometriomas: a randomized controlled trial
2021
Overview
Background
Ovarian endometrioma is a common gynecological disease that is often treated with surgery or hormonal treatment. Ovarian cystectomy, a surgical procedure for ovarian endometrioma, can result in impaired ovarian reserve.
Methods
We conducted a randomized controlled trial to evaluate the efficacy of hormonal treatment [gonadotropin-releasing hormone agonist (GnRHa) or dienogest (DNG)] for preserving ovarian reserve after cystectomy for ovarian endometrioma. The primary endpoint was the level of serum Anti-Müllerian hormone (AMH) as a marker of ovarian reserve.
Results
Before and after laparoscopic surgery, 22 patients in the GnRHa group and 27 patients in the DNG group were administered hormonal treatment for a total of 4 months. After 1-year follow-up, >60% of the patients in the DNG group retained over 70% of their pretreatment AMH levels, whereas no patient in the GnRHa group retained their AMH levels after cystectomy (
P
< 0.01). Interleukin-6 (IL-6) is a key cytokine involved in inflammation. Compared with the GnRHa group, patients in the DNG group had lower IL-6 levels at the end of treatment.
Conclusions
Our data revealed that DNG is more effective than GnRHa in preserving ovarian reserve after cystectomy of ovarian endometrioma. This is achieved through the reduction of the inflammatory response during the perioperative period and other endometriosis-related inflammatory reactions.
Trial registration
The registration number of this trial is UMIN-CTR, UMIN000018569, registered 6 August 2015,
https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021492
, and Japan Registry of Clinical Trials, jRCTs041180140, registered 29 March 2019,
https://jrct.niph.go.jp/en-latest-detail/jRCTs041180140
. This randomized controlled trial was conducted in accordance with the CONSORT guidelines.
Publisher
BioMed Central,BioMed Central Ltd,BMC
Subject
/ Agonists
/ Endometriosis - drug therapy
/ Enzymes
/ Female
/ Gonadotropin-releasing hormone
/ Gonadotropin-Releasing Hormone - agonists
/ Hormone Antagonists - therapeutic use
/ Humans
/ Medicine
/ Nandrolone - analogs & derivatives
/ Nandrolone - therapeutic use
/ Ovarian Reserve - drug effects
/ Ovaries
/ Patients
/ Surgery
/ Sutures
/ Urinary Bladder Diseases - drug therapy
/ Urinary Bladder Diseases - surgery
/ Values
